OncLive TV

Timothy Hughes, MD, MBBS, FRACP, FRCPA, on safety data for asciminib in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia.

Andrew Davis, MD, discusses the use of antibody-drug conjugates in breast cancer, highlighting recent updates with these agents in the treatment paradigm.

Noa Biran, MD, discusses the impact of the IMROZ trial in the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma.

Komal Jhaveri, MD, FACP, discusses the evolution of antibody-drug conjugates for patients with HER2-positive, HER2-low or HER2-ultralow metastatic breast cancer.

Antonio Cigliola, MD, discusses the phase 2 SURE-01 study of neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer.

Brian I. Rini, MD, FASCO discusses findings from an exploratory analysis of the phase 3 KEYNOTE-426 study.

Grzegorz S. Nowakowski, MD, discusses the significance of the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.

Adrienne G. Waks, MD, discusses implications of the potential use of first-line T-DXd in HER2-positive breast cancer.

Maurie Markman, MD, discusses an analysis of the association between obesity and the development of endometrial cancer.

Sam Brondfield, MD, MA, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses careers in medical education.

Ciara Kelly, MBBCh, BAO, discusses the current and potential roles for ripretinib in the gastrointestinal stromal tumor treatment paradigm.

Mark Agulnik, MD, discusses the evolving management of heterogeneous disease types in gastrointestinal stromal tumors.

Lova Sun, MD, MSCE, discussions safety implications observed from part C of the phase 2 innovaTV 207 trial.

Jerôme Fayette, MD, PhD, discusses findings from a trial of frontline petosemtamab plus pembrolizumab in patients with recurrent/metastatic HNSCC.

Jun Gong, MD, discusses the importance of molecular profiling when determining optimal treatments for patients with mCRPC.

Rebecca Klisovic, MD, discusses the early use of JAK inhibitors to treat younger patients with low-risk, newly diagnosed myelofibrosis.

Kedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.

Rohan Garje, MD, discusses the benefits of a multimodal approach for patients with small cell bladder cancer.

Cynthia Ma, MD, PhD, discusses unanswered questions regarding treatment sequencing for patients who develop CDK4/6 inhibitor–resistant breast cancer.

Arya Mariam Roy, MBBS discusses limitations of the Pathway trial evaluating the association between polygenic scores and survival outcomes in patients with breast cancer.

Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Marc-Oliver Grimm, MD discusses the clinical implications, short comings, and future steps following a post-hoc analysis from the phase 3 ARASENS trial.

Chun Chao, PhD, MS, discusses the association between the use of broad-spectrum antibiotics and the risk of developing early-onset colorectal cancer.

Mikkael A. Sekeres, MD, discusses a subgroup analysis of treatment with imetelstat in patients with low-to intermediate-1–risk myelodysplastic syndrome.

Noa Biran, MD, discusses the implications of findings from the phase 3 DREAMM-7 trial in multiple myeloma.

Ranee Mehra, MD, discusses long-term follow-up data from the phase 2 E3311 trial in patients with HPV-associated oropharynx cancer.

Sumanta Kumar Pal, MD, FASCO, discusses preliminary findings from a phase 1 dose-escalation study of DFF332 in patients with advanced ccRCC.

Alfred L. Garfall, MD, MS discusses updated long-term data for teclistamab in patients with relapsed/refractory multiple myeloma.

David Braun, MD, PhD discusses the selection of immune checkpoint inhibitor use in clear cell renal cell carcinoma